Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Innovative vs Generic Valganciclovir in Kidney Transplant Recipients
NCT03631316Completed
- Start
- Mar 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of valganciclovir in cytomegalovirus infection (CMV) (2 arms). Primary endpoint: Area Under the Curve at Day 4. Started Mar 2018; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT03631316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631316.